We describe the isolation and characterization of a new apaf-1-interacting protein (APIP) as a negative regulator of ischemic injury. APIP is highly expressed in skeletal muscle and heart and binds to the CARD of Apaf-1 in competition with caspase-9. Exogenous APIP inhibits cytochrome c-induced activation of caspase-3 and caspase-9, and suppresses cell death triggered by mitochondrial apoptotic stimuli through inhibiting the downstream activity of cytochrome c released from mitochondria. Conversely, reduction of APIP expression potentiates mitochondrial apoptosis. APIP expression is highly induced in mouse muscle affected by ischemia produced by interruption of the artery in the hindlimb and in C2C12 myotubes created by hypoxia in vitro, and the blockade of APIP up-regulation results in TUNELpositive ischemic damage. Furthermore, forced expression of APIP suppresses ischemia/hypoxia-induced death of skeletal muscle cells. Taken together, these results suggest that APIP functions to inhibit muscle ischemic damage by binding to Apaf-1 in the Apaf-1/ caspase-9 apoptosis pathway.
Apaf-1 has been identified as the mammalian homolog of Caenorhabditis elegans ced-4, which is a core component of the cell death machine (together with ced-3 and ced-4) and plays a crucial role in the general apoptotic program of normal development and pathogenesis (1) (2) (3) (4) . Understanding the pathways that lead to apoptosis and identifying strategies to regulate this pathway may have important clinical implications. In stressinduced apoptosis, mitochondria releases apoptogenic factors such as cytochrome c, AIF, Smac/Diablo, and serine protease HtrA2 (5-10). Pro-apoptotic members of the Bcl-2 family such as Bax and Bid induce the release of apoptogenic factors, whereas anti-apoptotic members such as Bcl-2 or Bcl-X L prevent their releases (11) . Bid is cleaved by caspase-8 and the truncated Bid (tBid) translocates to the mitochondria, where it triggers Bax activation (12) (13) (14) . Cytochrome c binds to Apaf-1 and, when dATP is added to the cytochrome c-bound Apaf-1, the oligomeric complex of Apaf-1 forms and leads to the recruitment of caspase-9 to form apoptosome and activates caspase-9 (15) (16) (17) .
Previous reports on Apaf-1 and caspase-9 knockout mice suggest that Apaf-1 is involved in the control of cell numbers in the developing brain, retina, face, and limbs. Apaf-1 and caspase-9 are essential for caspase-3 activation and seem to play important roles in normal development (18 -20) . Apaf-1-deficient mice exhibit reduced apoptosis in the brain and striking craniofacial abnormalities with hyperproliferation of neuronal cells. The thymocytes from Apaf-1 knockout mice fail to undergo apoptosis after treatment with various apoptotic stimuli. Apaf-1 and caspase-9 are also reported to control tumor development by functionally interacting with p53 (21) . Although some apoptosis regulated by Bcl-2 is activated independently of the apoptosome (22, 23) , these observations indicate that Apaf-1 plays a central role in the common events of mitochondria-dependent cell death pathways. Therefore, identification of such molecules as Boo and Hsp70 as regulators of Apaf-1-mediated cell death will be important (24 -26) .
Ischemia and reperfusion of skeletal muscle occurs in acute vascular occlusion and revascularization, in elective vascular surgery, in orthopedic surgery by means of a tourniquet, and in transplantation of muscle containing cutaneous flaps. Such ischemic injury to skeletal muscle induces free oxygen radical production, a loss of energy supply to the cell, a loss of cellular calcium homeostasis, or activation of apoptosis pathway (27, 28) . However, the control circuit to regulate ischemic damage to skeletal muscle is largely unknown.
In this study, we isolated and characterized the Apaf-1-interacting protein, APIP.
1 APIP is highly expressed in skeletal muscle and its expression regulates Apaf-1-mediated cell death. In particular, APIP expression is induced during ischemia as a necessary step leading to the suppression of hypoxiainduced muscle cell death.
EXPERIMENTAL PROCEDURES
Yeast Two-hybrid Assay-The CARD region (amino acids 1-89) of Apaf-1 was used as bait in conventional yeast two-hybrid screening using pLexA vector (Clontech, Palo Alto, CA) and Jurkat cDNA library (Stratagene, La Jolla, CA).
Plasmid Construction-The CARD of Apaf-1 was amplified by PCR and subcloned into the BamHЈ site of pLexA (pLexA-CARD). The mouse * This work was supported by a grant from the National Research Laboratory program (to Y-K. J.) and 21 C Frontier on Brain and Functional Analysis of Human Genomics of the Korean Ministry of Science and Technology. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. CARD of Apaf-1 was subcloned into BamHЈ and XhoЈ site of pcDNA-FLAG (pmCARD-FLAG). cDNAs encoding the full open reading frames of APIP and APIP2 were subcloned into the XhoЈ site of pcDNA3-HA (pHA-APIP) and pEGFP (pGFP-APIP). Antisense cDNAs of APIP and FADD were subcloned into pcDNA3-HA (pAS-APIP) and pEGFP (pAS-FADD), respectively. Deletion mutants of APIP were generated by PCR and subcloned into the XhoЈ site of pcDNA3-HA. To generate GST-APIP protein, the CARD of Apaf-1 and ⌬A (amino acids 16 -204) of APIP were subcloned into the BamHЈ site of pGEX5X-1 (pGEX-CARD and pGEX-APIP).
Antibody Generation-BL21 (DE3) was transformed with pGEX-APIP and incubated with 0.3 mM isopropyl-1-thio-␣-D-galactopyranoside. GST-APIP protein was purified by glutathione-Sepharose TM 4B beads (Amersham Biosciences) and injected four times into rabbit and mouse. Rabbit anti-APIP antibody was purified by antigen-affinity chromatography using SulfoLink kit (Pierce).
Northern Blot Analysis-Northern blotting was performed using multiple tissues. The Northern blot membrane was from Clontech, and a 32 P-labeled APIP probe was generated by the random prime kit (Amersham Biosciences).
Reagents-Apaf-1 (Ϫ/Ϫ) and caspase-9 (Ϫ/Ϫ) MEFs were previously described (19, 20) . Etoposide, cis-PLATINUM(II)-Diammine dichloride, and staurosporin were purchased from Sigma. Soluble Fas ligands were obtained from the cultured supernatant of CHO-K1-Fas cells grown in serum-free medium (CHO-S-SFM II; Invitrogen). Active specific anticaspase-9, anti-␣-tubulin, anti-rabbit IgG-horseradish peroxidase (HRP), anti-mouse IgG-HRP, anti-rat IgG-HRP, and anti-goat IgG-HRP antibodies were purchased from Santa Cruz; anti-Apaf-1 monoclonal antibody (2E12) was from Alexis (Lausen, Switzerland) (39); active specific anti-caspase-3 antibody was from Cell Signaling (Beverly, MA); anti-HA antibody was from Roche Applied Science (BM, Germany); anti-cytochrome c antibody was from BD Biosciences (Franklin Lakes, NJ); and anti-FLAG antibody was from Sigma.
In Vitro Binding Assay-The purified GST and GST-CARD coupled to glutathione-Sepharose 4B were incubated with [ 35 S]methionine-labeled APIP, its deletion mutants, and caspase-9S by a TNT-coupled transcription/translation system from Promega for 3 h at 4°C. After the GST pull-down assay, the precipitated proteins were washed with the binding buffer (50 mM Tris-HCl, pH 6.8, 100 mM NaCl, 1 mM dithiothreitol, 2 mM EDTA, 0.05% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, and 5% (v/v) glycerol), separated by 12% SDS-PAGE, and detected by autoradiogram.
Immunoprecipitation-HeLa and HEK293 cells were lysed in radioimmune precipitation assay buffer (50 mM Tris-HCl, pH 7.4, 1% Nonidet P-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 g/ml each of aprotinin, leupeptin, and pepstatin, 1 mM Na 3 VO 4 , and 1 mM NaF]. APIP was immunoprecipitated from cell lysates after incubation with anti-APIP antibody and protein G-Sepharose (Amersham Biosciences) for 3 h at 4°C. Immunocomplexes were centrifuged, washed with cold lysis buffer at least three times, and then detected with Western blot analysis.
Stable Transfection-C2C12 cells were transfected with 1 g of pHA-APIP using LipofectAMINE reagent from Invitrogen and then grown in selection medium containing 1 mg/ml of G418 for 2 weeks. After single cell cloning, the clones were screened by Western blot analysis.
Cell-free System-Preparation of HeLa S-100 fraction was previously described (4) . Briefly, a 3-l aliquot of the in vitro translated caspase-3 was incubated with 80 g of S-100 fraction in the presence or absence of 1 mM dATP, 2 g/ml cytochrome c, and 2 g or 10 g of purified GST or GST-APIP proteins for 1 h at 30°C. The reaction products were subjected to 15% SDS-PAGE and exposed to x-ray film.
Fractionation of Cell Extracts-Cells were incubated in hypotonic FIG. 1. Alignments of amino acid residues and tissue distribution of APIP. A, amino acid sequence of human APIP (hAPIP) was aligned to the sequence of mouse APIP (mAPIP), Drosophila melanogaster, and C. elegans. Identical amino acids are aligned, and conserved sequences are darkly shaded. B, APIP expression pattern was analyzed by Northern blotting using mRNA prepared from human adult tissues. The same membrane was probed with ␤-actin cDNA as an internal control.
buffer A (250 mM sucrose, 20 mM Hepes pH 7.5, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 1 mM phenylmethylsulfonyl fluoride, 1 g/ml each of aprotinin, leupeptin, and pepstatin, 1 mM Na 3 VO 4 , and 1 mM NaF) and lysed by homogenizer. Intact cells and nuclei were separated by centrifugation at 500 ϫ g for 5 min; the supernatants were then centrifuged at 10,000 ϫ g for 30 min to fractionate membrane pellet and cytoplasm.
Ischemia Induction in the Muscle of Mouse Hindlimb and TUNEL Assay-Ischemia was induced in 20 -25-g male C57BL/6 mice by ligation of the femoral artery of the hindlimb. The operative procedures to generate ischemic muscle were previously described (40) . The animals were anesthetized with pentobarbital intraperitoneally for the surgical procedure. The middle portion of the left hindlimb of the mouse was incised and ligated at both the proximal end of the femoral artery and the distal portion of the saphenous artery. All side and attached side branches were dissected free and then excised. The right hindlimbs of the mice were used as non-ischemic controls (n Ͼ 3, the number of mice). Mouse muscle tissues were injected with 25 g of pAS-APIP using a glass capillary. After 2 days, unilateral hindlimb ischemia was induced for an additional day, and the affected muscles were examined for apoptosis by TUNEL analysis with ApopTag in situ apoptosis detection kits (Intergen Company, Purchase, NY).
Hypoxia and Differentiation Induction of C2C12 Skeletal Muscle Cells-C2C12 cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 20% fetal bovine serum (EQ-UITE-Bio, Kerrville, TX) in the presence of 5% CO 2 . Cell differentiation of myoblasts into myotubes were induced by incubating 80% confluent C2C12 cells with 2% horse serum for 4 days. Hypoxia was achieved by culturing the cells in minimum essential medium (Invitrogen) in an air-tight Plexiglas chamber with GasPak Plus TM (BD Biosciences) as previously described (41) .
RESULTS

Isolation of APIP-
In an attempt to identify the Apaf-1-interacting protein, we screened the Jurkat cDNA library by using the CARD of Apaf-1 as bait for a yeast two-hybrid assay. From 10 million yeast transformants, we have isolated 12 putative positive clones including Hsp70. Among them, we designated an Apaf-1-interacting protein as APIP that is also described as CGI29 and MMRP19. APIP is predicted to encode a 204 amino acid protein containing the aldolase II domain and localizes on chromosome 11p13.11-11p13.12. In GenBank TM expressed-sequenced tag data base for human, we also found an isoform of APIP, APIP2 encoding a 242 amino acid protein, which is an alternative splicing variant from a single gene and different in its N terminus from APIP (Fig. 1A) . Sequence alignment shows that the amino acid sequence of APIP is highly conserved among different species. Analysis with the BLAST data base revealed that there is a single APIP gene in mice (mAPIP) that is more similar to APIP2. When examined with Northern blotting, the tissue distribution of APIP revealed a transcript of APIP with an approximate size of 1.2 kb that was ubiquitously expressed in most adult tissues with high expression in skeletal muscle, heart, and kidney (Fig. 1B) .
In a yeast two-hybrid assay, APIP interacted with the CARD of Apaf-1, but not with the death domain of FADD (data not shown). In vitro GST pull-down assays showed that APIP and APIP2 interacted with the GST-CARD fusion protein as efficiently as the caspase-9 short form did, but they did not interact with GST ( Fig. 2A) . APIP did not bind to other CARDcontaining proteins such as pro-caspase-9 (data not shown). The radiolabeled APIP pulled down by GST-CARD represented about 10% of input. The endogenous interaction of APIP and Apaf-1 was examined in HeLa cells. An immunoprecipitation assay using anti-APIP antibody showed that Apaf-1 and APIP were detected in the immunoprecipitates, indicating that endogenous APIP interacts with Apaf-1 in HeLa cells (Fig. 2B,  upper panel) . We also were able to demonstrate an interaction of exogenous Apaf-1 with APIP by an immunoprecipitation assay of HEK293F cells transfected with HA-tagged APIP and Apaf-1 (Fig. 2B, middle panel) . Intracellular interaction of APIP with the CARD of Apaf-1 was further examined after transfection with pmCARD-FLAG and pHA-APIP (Fig. 2B,  lower panel) . Western blot analysis with anti-FLAG antibody following immunoprecipitation with anti-HA antibody showed that APIP interacted with Apaf-1 via CARD in the cells. Subcellular fractionation analysis showed that APIP was found in the cytosol as Apaf-1 (data not shown).
Anti-apoptotic Activity of APIP in the Mitochondria-mediated Apoptosis-Apaf-1 functions as a cytochrome c-dependent activator of caspase-9. To examine the role of APIP in cell death, we generated a C2C12 skeletal muscle cell line that stably expressed APIP (C2C12/APIP) (Fig. 3A) . C2C12 or C2C12/APIP cells were exposed to various cell death stimuli. Determination of cell viability showed that overexpression of APIP suppressed apoptosis induced by etoposide, cisplatin, or staurosporin, stimuli that are known to activate the mitochondrial pathway, but APIP failed to suppress apoptosis triggered by soluble Fas ligand or TNF-␣ (Fig. 3A) . Such inhibitory activity of APIP was also observed over 3 days in C2C12 cells and in other cells such as HeLa and HEK293 cells treated with the mitochondrial stress signals (data not shown).
We further assessed the function of APIP in Apaf-1-mediated cell death. Immunocytochemical analysis showed that cytochrome c in the mitochondria was released into the cytosol of C2C12 cells exposed to etoposide and undergoing apoptosis (Fig. 3B) . However, expression of APIP-protected C2C12 cells from etoposide-induced apoptosis despite cytochrome c release from mitochondria. Fractionation analysis followed by Western blotting also showed that cytochrome c was released from the mitochondria in both C2C12/APIP and C2C12 cells exposed to etoposide (Fig. 3C, left panel) . In contrast to C2C12 cells, however, activation of caspase-9 or caspase-3, the downstream   FIG. 3 . Suppression of etoposide-and tBid-triggered cell death by APIP without affecting cytochrome c release from mitochondria. C2C12 or C2C12 cells stably expressing APIP (C2C12/APIP) were left untreated (CTRL) or exposed to etoposide (Etop., 25 g/ml), cisplatin (Cisp., 100 ng/ml), staurosporin (Stau., 50 nM), TNF-␣ (TNF/CHX, 30 ng/ml), or soluble Fas ligand (s-Fas, 0.2 g/ml) for 24 h. A, cell viability (% of cell death) was determined by trypan blue and TUNEL assays. B, cells exposed to etoposide (25 g/ml) were stained with anti-cytochrome c antibody and Hoechst 33258. The arrows indicate the typical diffused and cytosolic pattern of cytochrome c and morphology of nuclei in the same cells. C, C2C12 and C2C12/APIP cells were treated with etoposide (Etop., 50 g/ml) for 12 h. Cell extracts were separated into membrane and cytosolic fractions, and the fractionated extracts were subsequently immunoblotted with anti-cytochrome c, anti-COX4, or anti-tubulin antibody (left panel). The cell extracts were also probed with anti-active caspase-9, anti-active caspase-3, or anti-tubulin antibody (right panel). Asterisk (*) indicates nonspecific signal. D, HeLa cells were transfected with ptBid alone or together with pGFP-APIP or pGFP-APIP2 for 24 h. Cell viability was then determined based on the morphology of GFP-positive cells. Bars depict means Ϯ S.D. from at least four independent experiments. E, wild type, Apaf-1 (Ϫ/Ϫ), or caspase-9 (Ϫ/Ϫ) MEFs were transfected with pGFP or pGFP-APIP for 24 h and then exposed to etoposide (Etop., 25 g/ml) or TNF-␣ (TNF/CHX, 10 ng/ml) for 12 h. Cell viability (% of cell death) was determined by trypan blue assays of GFP-positive cells. Bars depict means Ϯ S.D.
caspases of cytochrome c, was suppressed in the etoposidetreated C2C12/APIP cells (Fig. 3C, right panel) . These results indicate that APIP protects cells from apoptosis by inhibiting the downstream activity of cytochrome c released from mitochondria. To explore the role of APIP as an apoptosis suppressor, HeLa cells were transiently transfected with tBid, the cleavage product of Bid by caspase-8. The tBid-triggered apoptosis was efficiently suppressed by co-expression of APIP (death rates from 62 to 35%) (Fig. 3D) , indicating that APIP functions as an anti-apoptotic molecule in the mitochondriamediated cell death pathway.
Anti-apoptotic activity of APIP was examined in Apaf-1 (Ϫ/Ϫ) or caspase-9 (Ϫ/Ϫ) mouse embryo fibroblasts (MEFs). As reported earlier, Apaf-1 (Ϫ/Ϫ) or caspase-9 (Ϫ/Ϫ) MEFs were resistant to cell death triggered by etoposide but not by TNF/ CHX (Fig. 3E) . Overexpression of APIP in the wild-type MEFs suppressed etoposide-induced cell death to the level of Apaf-1 (Ϫ/Ϫ) or caspase-9 (Ϫ/Ϫ) MEFs. The anti-apoptotic function of APIP was further examined by using antisense approaches. Direct targeting of APIP expression with antisense cDNA potently increased apoptosis induced by cisplatin but not by soluble Fas ligand, while antisense cDNA of FADD inhibited apoptosis in the opposite manner in HEK293 cells (Fig. 4A) . Expression of antisense cDNAs of APIP in HEK293 and HeLa cells apparently diminished the expression level of APIP as determined by Western blot (Fig. 4B ) and immunocytochemical analysis (data not shown), respectively. Similarly, antisense cDNA of FADD reduced expression level of FADD and was used as a control for the non-mitochondrial apoptotic signal. These results are more illustrative of the role of APIP as an antiapoptotic molecule.
Suppression of Cytochrome c-mediated Activation of Caspase-3 and Caspase-9 -
The CARD of caspase-9 binds to the CARD of Apaf-1 for its activation. As molecules interacting with the CARD of Apaf-1, competitive binding between caspase-9 and APIP to Apaf-1 was examined in vitro (Fig. 5A) . In vitro GST pull-down assays showed that increasing the amounts of caspase-9 in the reaction mixtures proportionally reduced the amounts of APIP interacting with the CARD of Apaf-1, while binding of caspase-9 to the CARD of Apaf-1 gradually increased. These results indicate that APIP and caspase-9 may compete with each other for binding to Apaf-1. To examine the anti-apoptotic activity of APIP in Apaf-1-mediated activation of caspase, a cell-free system containing S-100 fraction was employed. Incubation of S-100 fraction with dATP and cytochrome c induced proteolytic activation of caspase-3 and caspase-9 (Fig. 5B) . However, activation of caspase-3 and caspase-9 were suppressed by incubating the S-100 fraction with purified GST-APIP, but not with GST, suggesting that APIP inhibited the cytochrome c-mediated activation of caspase and further supporting the intracellular anti-apoptotic activity of APIP functioning downstream of the cytochrome c released from mitochondria, as shown in Fig. 3, B and C. Anti-apoptotic Activity of APIP Core Region-To map the functional domain of APIP in detail, we constructed several deletion mutants (Fig. 5C ). The 35 S-labeled deletion mutants of APIP were evaluated for their abilities to bind to the CARD of Apaf-1 protein in vitro (Fig. 5D) . Although the ⌬C mutant of APIP showed relatively weak interaction with Apaf-1, all deletion mutants we generated bound to GST-CARD. Subsequently, the ability of each mutant to suppress cell death was examined in HeLa cells with transient expression analysis (Fig. 5E) . Interestingly, only the ⌬A mutant containing the common core region (amino acids 16 -204 of APIP) of both APIP and APIP2 was as effective as APIP in suppressing cisplatin-or etoposide-induced apoptosis, whereas other mutants showing further deletion lost their abilities to exhibit the anti-apoptotic activity. Further, in vitro competition assay between caspase-9 and either APIP or APIP deletion mutants showed that the binding of caspase-9 to the CARD of Apaf-1 was effectively decreased by the increased amounts of APIP and ⌬A mutant, but not by ⌬D mutant (Fig. 5F ). These results indicate that the wild type and ⌬A mutant, but not the ⌬D mutant, of APIP compete with caspase-9 to interact with the CARD of Apaf-1, consistent with the inhibitory activities of the mutants used in Fig. 5E . These results suggest that although the N-or Cterminal region of APIP is able to interact with the CARD of Apaf-1 in vitro, a core region spanning residues 16 -204 of APIP seems to be required for anti-apoptotic activity of APIP.
Block of Muscle Ischemic Damage by Induced Accumulation of APIP-Messenger RNA of APIP was abundant in skeletal muscle (Fig. 1B) . To examine whether APIP was implicated in ischemic injury, the expressional regulation of APIP was investigated in the ischemia-induced mouse muscle. Western blotting and immunostaining analyses showed that interruption of the artery in the hindlimb muscle transiently induced dramatic accumulation of mAPIP, but not of Bcl-xL, cIAP1, or Bid (Fig.  6A and data not shown) . The specificity of anti-APIP antibody was examined by Western blotting of muscle lysates (Fig. 6B,  right panel) . In contrast to the non-treated hindlimbs, the level of mAPIP protein was the highest (8-fold) at day 1 of the prolonged ischemia and returned to the control level at day 7. Interestingly, apoptotic cells were rarely observed in the ischemic muscle as examined with TUNEL assay and Hoechst dye staining (Fig. 6D) . We then targeted the expression of mAPIP by directly injecting expression plasmid encoding antisense cDNA of APIP into mouse skeletal muscle. When the vector expressing green fluorescence protein was injected, green fluorescence was detected as early as day 1 and remained for at least 5 days in muscle tissues (data not shown). Ischemiainduced accumulation of mAPIP was abolished by injecting antisense cDNA of APIP into the muscle tissues (Fig. 6C) . TUNEL staining detected massive dying cells in the tissue samples prepared from the hindlimb muscles injected with antisense cDNA of APIP, but not in those injected with pcDNA3 (Fig. 6D, arrowheads) . These results suggest that the accumulation of mAPIP blocks ischemia-induced cell death of affected skeletal muscle.
To ascertain the inhibitory effects of APIP on ischemic/hypoxic damage, we examined ischemic damage of the C2C12 skeletal muscle cell line. Unlike muscle tissues, there was no change in the expression level of mAPIP in C2C12 myoblast cells under in vitro ischemic/hypoxic conditions (data not shown). While incubation of C2C12 myoblasts under hypoxic conditions for 1 day induced 50% of cell death, expression of APIP completely suppressed ischemia/hypoxia-induced death of C2C12 myoblast cells to the control level (Fig. 7A) . Examination of cell extracts prepared from C2C12 and C2C12/APIP cells with Western blotting showed that hypoxia-induced activation of caspase-9 S-labeled, in vitro translated caspase-9. The reaction volumes and the amounts of total protein were adjusted same by adding reticulocyte lysate containing in vitro translated luciferase to the reaction mixture. After GST pull-down assay, the precipitated proteins were separated by SDS-PAGE and exposed to x-ray film. Lower graph indicates densitometric analysis of APIP protein remaining on GST-CARD. B, HeLa S-100 fraction (80 g) was incubated with different amounts of purified GST or GST-APIP and in vitro translated, 35 S-labeled caspase-3 (upper panel) or caspase-9 (lower panel) in the presence or absence of cytochrome c (2 g/ml) and dATP (1 mM). The reaction products were separated by SDS-PAGE and exposed to x-ray film. C, schematic diagram of the APIP deletion mutants (⌬). Numbers indicate amino acid residues of APIP. D, in vitro binding assays were performed using purified GST-CARD and APIP deletion mutants labeled with [ 35 S]methionine. The reaction products were fractionated by 15% SDS-PAGE and exposed to x-ray film. E, HeLa cells were transiently co-transfected with pEGFP and various deletion mutants of APIP for 24 h, and then exposed to etoposide (Etop., 25 g/ml), cisplatin (Cisp., 100 ng/ml), or soluble Fas ligand (s-Fas, 200 ng/ml) for additional 24 h and cell viability was determined. F, purified GST-CARD was incubated with in vitro translated caspase-9 in the presence of different amounts of in vitro translated APIP or its deletion mutant proteins. The reaction volumes were adjusted same by adding reticulocyte lysate. After GST pull-down assay, the precipitated proteins were separated by SDS-PAGE and exposed to x-ray film.
was suppressed in C2C12/APIP cells (Fig. 7B) , indicating that APIP inhibits hypoxia-induced activation of caspase-9.
We then examined cell viability of C2C12 myotube cells after induction of in vitro differentiation. Interestingly, C2C12 skeletal myotubes were more resistant to hypoxic damage compared with the myoblast cells (Fig. 7C) . In contrast to myoblasts, mAPIP protein was transiently induced in C2C12 myotubes in response to hypoxia (Fig. 7D) , consistent with that of in vivo muscle tissues under ischemic condition and further supporting the finding that the increased expression of mAPIP protects C2C12 muscle cells from ischemia/hypoxia-induced cell death. DISCUSSION We have identified a novel anti-apoptotic molecule in Apaf-1-mediated cell death, APIP. Apaf-1, a key regulator of apoptosis, has a major role in programmed cell death (4) . In the presence of cytochrome c and dATP, Apaf-1 oligomerizes to form a very large protein complex, apoptosome (17) . Apoptosome recruits and activates caspase-9, and is regulated by several factors including XIAP and heat shock proteins (25, 26, 29) . Hsp70 has been reported to associate with Apaf-1 and inhibit cell death by interfering with the ability of cytochrome c and Apaf-1 to recruit caspase-9. In this study, we have provided several lines of evidence demonstrating that APIP is likely to interact with Apaf-1 and consequently inhibit Apaf-1-mediated activation of caspase-9: (i) APIP bound to Apaf-1 in vitro and in vivo; (ii) APIP inhibited cytochrome c-induced activation of caspase-9 and cell death; (iii) APIP expression suppressed apoptosis induced by the mitochondrial insults including expression of tBid, etoposide, cisplatin, or hypoxia, but not by soluble Fas ligand or TNF-␣; and (iv) down-regulation of APIP expression potentiated mitochondria-mediated cell death. Suppression of etoposide-induced cell death by APIP expression was as similar as that of Apaf-1 (Ϫ/Ϫ) or caspase-9 (Ϫ/Ϫ) MEFs.
APIP negatively regulates Apaf-1-mediated cell death through a central core domain spanning the common region of APIP and APIP2. APIP and caspase-9 competed to bind to the CARD of Apaf-1 in vitro, indicating that the binding regions of caspase-9 and APIP in Apaf-1 overlap. However, additional region of Apaf-1 may participate in the protein-protein interaction with APIP because, unlike caspae-9, APIP could form complex with Apaf-1 in the absence of dATP and cytochrome c as examined with immunoprecipitation assay. There is no apparent CARD domain in APIP, which is frequently found in caspases, Apaf-1, and other CARD-containing molecules. Instead, a broad core region spanning residues 16 -204 of APIP seems to be required for the inhibitory activity of APIP in Apaf-1-mediated cell death, probably through an unidentified structural motif. In that case, amino acid sequences of APIP are highly conserved from C. elegans to humans with the exception at the N terminus, showing 52% amino acid sequence homology, although two extra short stretches of APIP are found in C. elegans.
APIP may function under pathological conditions. Hypoxia is an important factor in the pathogenesis of several major diseases such as stroke and cancer (30 -32) . Several lines of evidence indicate that, under certain conditions, hypoxia induces cell death through the Apaf-1-mediated mitochondrial pathway (33) . Hypoxia results in translocation of Bax from the cytosol to the mitochondria and activation of caspases (34 -38) . In addition, the cells overexpressing the anti-apoptotic Bcl-2 family proteins have been shown to prevent hypoxia-induced apoptosis by inhibiting the release of cytochrome c (34) . Thus, apoptotic signals during hypoxia seem to occur through the release of cytochrome c and the Apaf-1-mediated activation of caspase-9 (36).
Interestingly, the expression level of mAPIP was highly and transiently up-regulated in the muscle tissues not showing any significant damage during ischemia. Though the difference in the expression level of mAPIP in the ischemic hindlimb muscles at day 3 may reflect the individual differences, we consistently observed transient up-regulation of mAPIP at earlier times. The observation that expression levels of mAPIP affected ischemia/hypoxia-induced death of muscle cells in vivo and in vitro led us to propose that the induction of APIP under ischemic conditions suppressed ischemic injury in the affected muscles. Thus, the observed recovery from muscle ischemic injury in mice was probably due to up-regulation of mAPIP in the affected muscle for a short period and the formation of a bypass blood vessel network in the prolonged period. The ability of APIP to prevent cell death during hypoxia is believed to be associated with Apaf-1, although it is not clear that this inhibitory effect also blocks apoptosome formation. At present, while the molecular architecture of the APIP/Apaf-1 complexes in living and dying cells remains to be determined, the binding of APIP to CARD of Apaf-1 may prevent caspase-9 from being recruited into the apoptosome under ischemia/hypoxia. Taken together, the data presented here suggest that the anti-apoptotic function of APIP lies in the inhibition of downstream activity of cytochrome c released from mitochondria during pathogenic processes including muscle ischemia, suggesting a potential means by which APIP in pathogenic cell death may be manipulated.
